In recent years, nivolumab – which has been approved in Europe since June 2017 for adults with squamous cell carcinoma of the head and neck -has repeatedly been subject to early benefit assessments conducted by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) for other oncological indications.
The IQWiG has now investigated whether the drug, marketed by US pharma major Bristol-Myers Squibb (NYSE: BMY) under the trade name Opdivo, has an added benefit for patients in a new therapeutic indication.
According to the findings, there is an indication of considerable added benefit for patients who have progressed during platinum-based chemotherapy or up to six months after completion of this treatment. No data were available for patients with later progression. Hence for these patients, an added benefit of nivolumab in comparison with the appropriate comparator therapy is not proven.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze